BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 28730338)

  • 1. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
    Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
    Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Jagged1 modulated tumor-associated macrophage differentiation predicts poor prognosis in patients with invasive micropapillary carcinoma of the breast.
    Liu H; Wang J; Liu Z; Wang L; Liu S; Zhang Q
    Medicine (Baltimore); 2017 Apr; 96(16):e6663. PubMed ID: 28422875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.
    Choi HJ; Lui A; Ogony J; Jan R; Sims PJ; Lewis-Wambi J
    Breast Cancer Res; 2015 Jan; 17(1):6. PubMed ID: 25588716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
    Varešlija D; McBryan J; Fagan A; Redmond AM; Hao Y; Sims AH; Turnbull A; Dixon JM; Ó Gaora P; Hudson L; Purcell S; Hill AD; Young LS
    Clin Cancer Res; 2016 Jun; 22(11):2765-77. PubMed ID: 26763249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
    Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
    BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
    Berstein LM; Yue W; Wang JP; Santen RJ
    Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
    Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
    Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
    Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer.
    Ali A; Creevey L; Hao Y; McCartan D; O'Gaora P; Hill A; Young L; McIlroy M
    Breast Cancer Res; 2015 Sep; 17(1):123. PubMed ID: 26341737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
    Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
    Bacci M; Giannoni E; Fearns A; Ribas R; Gao Q; Taddei ML; Pintus G; Dowsett M; Isacke CM; Martin LA; Chiarugi P; Morandi A
    Cancer Res; 2016 Mar; 76(6):1615-26. PubMed ID: 26795347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.
    Ribas R; Ghazoui Z; Gao Q; Pancholi S; Rani A; Dunbier A; Dowsett M; Martin LA
    Breast Cancer Res; 2014 Oct; 16(5):447. PubMed ID: 25358600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients.
    Xuan QJ; Wang JX; Nanding A; Wang ZP; Liu H; Lian X; Zhang QY
    Pathol Oncol Res; 2014 Jul; 20(3):619-24. PubMed ID: 24414992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of tumor-associated macrophages in breast carcinoma invasion and metastasis.
    Yang J; Li X; Liu X; Liu Y
    Int J Clin Exp Pathol; 2015; 8(6):6656-64. PubMed ID: 26261547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.
    Medrek C; Pontén F; Jirström K; Leandersson K
    BMC Cancer; 2012 Jul; 12():306. PubMed ID: 22824040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wenshen Zhuanggu formula mitigates breast cancer bone metastasis through the signaling crosstalk among the Jagged1/Notch, TGF-β and IL-6 signaling pathways.
    Wu C; Chen M; Sun Z; Ye Y; Han X; Qin Y; Liu S
    J Ethnopharmacol; 2019 Mar; 232():145-154. PubMed ID: 30576770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.